C
Chanchal Goswami
Publications - 5
Citations - 1754
Chanchal Goswami is an academic researcher. The author has contributed to research in topics: Ramucirumab & Adverse effect. The author has an hindex of 3, co-authored 4 publications receiving 1495 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
Kei Muro,Jae Yong Cho,György Bodoky,Chanchal Goswami,Yee Chao,Lucas Vieira dos Santos,Yasuhiro Shimada,Eldar Topuzov,Eric Van Cutsem,Josep Tabernero,John Zalcberg,Ian Chau,Stefano Cascinu,Rebecca Cheng,Yanzhi Hsu,Michael Emig,Mauro Orlando,Charles S. Fuchs +17 more
TL;DR: Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young and elderly patients.
Journal ArticleDOI
Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.
Kei Muro,Jae Yong Cho,György Bodoky,Chanchal Goswami,Yee Chao,Lucas Vieira dos Santos,Yasuhiro Shimada,Eldar Topuzov,Eric Van Cutsem,Josep Tabernero,John Zalcberg,Ian Chau,Rebecca Cheng,Yanzhi Hsu,Michael Emig,Mauro Orlando,Hansjochen Wilke,Charles S. Fuchs +17 more
TL;DR: Baseline characteristics were generally well balanced between arms amongst the age subgroups and STEPP analysis revealed no obvious patterns for differential risks in terms of efficacy and AEs.
Journal ArticleDOI
O-0008regard phase 3, randomized trial of ramucirumab in patients with metastatic gastric or gej adenocarcinoma following progression on first-line chemotherapy
Josep Tabernero,Jiri Tomasek,Dumitru Filip,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Dos Santos,Giuseppe Aprile,David Ferry,Jae Yong Cho,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,Ian Chau,Jonathan D. Schwartz,Minori Koshiji,Yanzhi Hsu,Charles S. Fuchs +18 more
Journal ArticleDOI
EP216/#881 Safety and tolerability of olaparib in Indian patients with ovarian cancer: the prospective, single-arm, phase 4 soli trial
Joydeep Ghosh,Chandan Krushna Das,Ajay Gogia,G. Biswas,Chirag S. Desai,Sajjan Rajpurohit,Prashant Mehta,Keechilat Pavithran,Chanchal Goswami,Krishnakumar Rathnam,Sewanti Limaye,Vineet Talwar,Ajay K. Singh,Amit Dutta,Rohit Kodagali,Sudeep Gupta +15 more
TL;DR: In this paper , a prospective, single-arm, multicentre, phase 4 study in India (ClinicalTrials.gov Identifier: NCT04330040), eligible females (≥18 years) with PSR OC, in complete response (CR) or partial response (PR) to preceding platinum-based chemotherapy, received olaparib (300 mg BD) for 182 days or until its discontinuation.